Literature DB >> 11333866

The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis.

M Gabolde1, D Hubert, M Guilloud-Bataille, C Lenaerts, J Feingold, C Besmond.   

Abstract

Chronic liver disease is a major complication of cystic fibrosis. Its incidence and severity show marked heterogeneity, even among the homogeneous group of homozygous DeltaF508 patients, suggesting that environmental or genetic factors other than the deletion DeltaF508 may influence the development of cystic fibrosis related liver disease. We investigated whether the allelic variants of mannose binding lectin, an important protein of the immune system, could be associated with the presence of cirrhosis in a population of 216 homogeneous homozygous DeltaF508 patients. Analysis of the data shows that the presence of cirrhosis in cystic fibrosis patients is significantly associated with a mutated mannose binding lectin genotype (homozygous or compound heterozygous for mannose binding lectin variants). The modulating role of mannose binding lectin in the occurrence of cirrhosis in cystic fibrosis could be explained by the fact that hepatotoxic damage from viruses or bacteria might be increased by the immunodeficiency associated with mannose binding lectin variants and might facilitate the degradation of liver status. These data highlight the crucial role of mannose binding lectin in the clinical outcome of cystic fibrosis, as it has recently been shown that the mannose binding lectin gene is a modulating gene of the respiratory involvement in cystic fibrosis patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333866      PMCID: PMC1734861          DOI: 10.1136/jmg.38.5.310

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  12 in total

1.  Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study.

Authors:  M Gabolde; M Guilloud-Bataille; J Feingold; C Besmond
Journal:  BMJ       Date:  1999-10-30

2.  The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).

Authors:  E Kerem; M Corey; B S Kerem; J Rommens; D Markiewicz; H Levison; L C Tsui; P Durie
Journal:  N Engl J Med       Date:  1990-11-29       Impact factor: 91.245

3.  Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection.

Authors:  M F Yuen; C S Lau; Y L Lau; W M Wong; C C Cheng; C L Lai
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

4.  Natural history of liver disease in cystic fibrosis.

Authors:  A Lindblad; H Glaumann; B Strandvik
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

5.  Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis.

Authors:  P Garred; T Pressler; H O Madsen; B Frederiksen; A Svejgaard; N Høiby; M Schwartz; C Koch
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

6.  Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis.

Authors:  J Hull; A H Thomson
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

7.  Molecular basis of opsonic defect in immunodeficient children.

Authors:  M Sumiya; M Super; P Tabona; R J Levinsky; T Arai; M W Turner; J A Summerfield
Journal:  Lancet       Date:  1991-06-29       Impact factor: 79.321

8.  Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients.

Authors:  M Matsushita; M Hijikata; M Matsushita; Y Ohta; S Mishiro
Journal:  J Hepatol       Date:  1998-11       Impact factor: 25.083

9.  The major histocompatibility complex influences the development of chronic liver disease in male children and young adults with cystic fibrosis.

Authors:  A Duthie; D G Doherty; P T Donaldson; R Scott-Jupp; M S Tanner; A L Eddleston; A P Mowat
Journal:  J Hepatol       Date:  1995-11       Impact factor: 25.083

Review 10.  Liver and biliary problems in cystic fibrosis.

Authors:  C Colombo; P M Battezzati; M Strazzabosco; M Podda
Journal:  Semin Liver Dis       Date:  1998       Impact factor: 6.115

View more
  12 in total

Review 1.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

2.  Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship.

Authors:  M Carlsson; A G Sjöholm; L Eriksson; S Thiel; J C Jensenius; M Segelmark; L Truedsson
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

3.  The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease.

Authors:  Peter J Lewindon; Tamara N Pereira; Anita C Hoskins; Kim R Bridle; Richard M Williamson; Ross W Shepherd; Grant A Ramm
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

4.  Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin.

Authors:  Kenneth Ahrend Petersen; Finn Matthiesen; Teit Agger; Leif Kongerslev; Steffen Thiel; Karen Cornelissen; Mads Axelsen
Journal:  J Clin Immunol       Date:  2006-08-09       Impact factor: 8.317

Review 5.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

6.  Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials.

Authors:  Nicole Mayer-Hamblett; Margaret Kloster; Bonnie W Ramsey; Michael R Narkewicz; Lisa Saiman; Christopher H Goss
Journal:  Contemp Clin Trials       Date:  2012-11-29       Impact factor: 2.226

7.  Unexpected diagnosis of cystic fibrosis at liver biopsy: a report of four pediatric cases.

Authors:  Sophie Collardeau-Frachon; Raymonde Bouvier; Catherine Le Gall; Christine Rivet; Faiza Cabet; Gabriel Bellon; Alain Lachaux; Jean-Yves Scoazec
Journal:  Virchows Arch       Date:  2007-06-07       Impact factor: 4.064

Review 8.  Chronic pancreatitis and cystic fibrosis.

Authors:  H Witt
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

9.  Genetic modifiers of liver disease in cystic fibrosis.

Authors:  Jaclyn R Bartlett; Kenneth J Friedman; Simon C Ling; Rhonda G Pace; Scott C Bell; Billy Bourke; Giuseppe Castaldo; Carlo Castellani; Marco Cipolli; Carla Colombo; John L Colombo; Dominique Debray; Adriana Fernandez; Florence Lacaille; Milan Macek; Marion Rowland; Francesco Salvatore; Christopher J Taylor; Claire Wainwright; Michael Wilschanski; Dana Zemková; William B Hannah; M James Phillips; Mary Corey; Julian Zielenski; Ruslan Dorfman; Yunfei Wang; Fei Zou; Lawrence M Silverman; Mitchell L Drumm; Fred A Wright; Ethan M Lange; Peter R Durie; Michael R Knowles
Journal:  JAMA       Date:  2009-09-09       Impact factor: 56.272

10.  Genetic influences on cystic fibrosis lung disease severity.

Authors:  Colleen A Weiler; Mitchell L Drumm
Journal:  Front Pharmacol       Date:  2013-04-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.